Orchestra BioMed
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
150 Union Square Dr, New Hope, Pennsylva...Phone Number
(215) 862-5797Website
www.orchestrabiomed.comRevenue
$32 MillionStock Symbol
OBIOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Orchestra BioMed
Orchestra BioMed Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.Explore more
Orchestra BioMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orchestra BioMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Orchestra BioMed launches new products
Click to see if Orchestra BioMed had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Orchestra BioMed
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Orchestra BioMed recently announced quarterly report
Funding: Get notified immidiatlly once Orchestra BioMed has new funding data
Orchestra BioMed, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Orchestra BioMed has recently received funding, and reach out quickly before it becomes old news!
Check out if Orchestra BioMed is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Orchestra BioMed
Compare insights from companies similar to Orchestra BioMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Orchestra BioMed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orchestra BioMed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orchestra BioMed.
Orchestra BioMed financials insights
Gather financial insights about Orchestra BioMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Private Equity
$41M
2019
Other Financing Round
$34M
Debt
$20M
2022
Series D
$110M
2025
Unspecified
$70M
2026
Unspecified
$20M
Orchestra BioMed Tech Stack
A closer look at the technologies used by Orchestra BioMed
Most Recent Scoops
Person-Based
Events
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Orchestra BioMed is conducting the BACKBEAT global pivotal trial for AVIM therapy in partnership with Medtronic, enrolling up to 316 patients across sites in the US, Europe, and China, with enrollment nearing completion and targeted for the end of next quarter. The trial randomizes patients with uncontrolled hypertension receiving Medtronic dual-chamber pacemakers on a blinded basis, with primary endpoints assessed at 3 months measuring 24-hour ambulatory blood pressure superiority and freedom from unanticipated serious adverse device events, plus additional data through 12 months.
Medical Research, Clinical Operations
Project
Medical Research, Pharmaceuticals
Orchestra BioMed News & Media
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day.Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also host one-on-one meetings with investors that day and on Wednesday, Sept. 9.Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the second quarter ended June 30, 2026, and provided a business update on its two pivotal-stage cardiovascular programs: Atrioventricular Interval Modulation Therapy ("AVIM Therapy") for the treatment of uncontrolleOrchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orchestra BioMed
Sign Up For FreeTo access detailed company insights
Orchestra BioMed Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosc... Read More
